Key Takeaways
- Revenue crosses ₹500 crore for the first time: Consolidated quarterly revenue hit ₹506.9 crore, driven by international formulations, even as domestic acute therapies dragged.
- Margin squeezed by freight and materials: EBITDA margin fell to 9.2%, with ₹13 crore in additional freight costs from geopolitical conflict and a 30% rise in COGS and raw material costs washing out operational gains.
- Domestic story is a tale of two portfolios: Priority therapies grew ~30% while seasonal acute brands degrew by a similar magnitude, leaving domestic revenue down YoY; management expects new launches to reduce this dependence.
- USFDA outcome is the binary catalyst: A response update has been submitted; management feels confident of a positive outcome, with the earliest clarity expected by the first week of December 2026.
- What to watch next quarter: Whether emerging markets recover as promised by Q3, the USFDA decision in December, and any sign that freight cost pressure is easing.
Domestic Formulations: The Acute-Seasonal Hit
- Revenue decline driven by three brands: Domestic revenue fell to ₹212.8 crore from ₹226.1 crore YoY, as Febrex Plus, Oxipod, and ATL degrew by almost similar percent of a similar value to the 30% growth delivered by Cyclopam, Cital, and the dental portfolio.
- Season, not demand, is the culprit: Anti-infectives and respiratory categories suffered from a difficult season with lower footfall at general practitioners; Febrex Plus is actually growing at the prescription level despite the heavy sales decline.
- New products are the hedge: Almost ₹100 crore on a MAT basis now comes from products launched in the last two years, all in growth segments; as these stabilize, dependence on the seasonal acute portfolio should reduce.
- High single-digit growth still the target: Management believes sharper execution, stronger field force productivity, and disciplined brand investments will progressively strengthen domestic trajectories, and is working hard to achieve its FY27 domestic growth promise.
Aditi Panandikar: "It is very surprising that when Cyclopam and Cital and the dental portfolio is growing by 30%. So, you have three winners and then you have Febrex Plus, Oxipod and ATL degrew by almost similar percent of a similar value. That has been literally the story of this quarter."
International Formulations: Regulated Markets Lead
- Regulated markets grew 21.1%: Europe grew 23.5%, the US 16.4%, and South Africa/ANZ 31.2%, while emerging markets were flat at ₹61.2 crore versus ₹61.8 crore, dragging total international growth to 12.1%.
- Emerging markets underperformed for two quarters: Around ₹10 crore of sales was lost because the Sunways ophthal portfolio in Africa no longer belongs to Indoco; management expects recovery by Q3 FY27, with the fourth quarter typically strong for emerging markets.
- Europe and UK target 20%+ growth: Management has set a target of 20% plus growth for Europe and the UK over the next 1-2 years, supported by MMP-driven efficiency gains and a healthier future portfolio from filings already done.
- Plant capacity supports 4X international topline: With current infrastructure, the company can scale international revenue to four times current levels without major new CAPEX.
Aditi Panandikar: "With this infrastructure, the company can very well go to 4X the kind of topline we are delivering for international."
USFDA: The December Binary
- Response update submitted: Indoco has finished giving the FDA a major outline on how it will respond to concerns, and one update on data and work done thereafter has gone to the agency; the earliest clarity on the outcome is expected by the first week of December.
- Observations are procedural, not integrity-related: Management stated the seven observations are not related to data integrity, cleanliness, or cleaning validation, but mostly concern investigation procedures and processes; detailed discussion was deferred until after the outcome is known.
- Confidence is high but unvalidated: Management feels "pretty confident" of a positive outcome, though the agency has not yet responded; the US market remains the preferred single market over fragmented Europe, at least until December.
Aditi Panandikar: "I feel pretty confident that our team because the observations might look many in number, but none of them are specifically related to any DI, data integrity, any cleanliness or cleaning validation or any of those major things. Most of them have got to do with the expectation of the agency on how we investigate, how we do certain procedures and processes."
Margins: External Shocks Overwhelm Internal Gains
- Freight and materials drove the squeeze: Consolidated EBITDA margin at 9.2% was hit by a 30% increase in COGS, raw materials, freight, and solvents; freight alone added ₹13 crore in costs due to the ongoing geopolitical conflict, washing out gains from MMP work and headcount reduction.
- Employee cost ratio improved: Employee costs as a percentage of sales dipped by a couple of percentage points, but other expenses rose due to freight.
- Future margin levers are structural: When the new product portfolio (first-to-file, patents coming off in the next couple of years) starts coming into manufacturing sites, return per unit manufactured will be much higher; MMP work delivering more product from fewer batches will incrementally help margins, especially for Europe and the UK.
- Quantification is off the table for now: Management declined to quantify MMP savings or incremental EBITDA per ₹100 crore of revenue addition, calling it "very foolish in these times" given external environment variables that can wash out internal gains.
Aditi Panandikar: "It is very foolish in these times to make any of these comments. For example, all the MMP work we did, which should have resulted in positive, and then one impact of an external environment, it again gets washed out."
Warren: Restructuring and Long Investment Cycles
- Warren Life Sciences incorporated: A new company has been registered with the intent of possibly separating the API business and the OTC business of Warren Remedies, which management described as "as different as chalk and cheese."
- Toothpaste near breakeven, but not the priority: Warren toothpaste almost broke even this quarter, partly because some advertising expenditures were slowed down; management wants to concentrate on growing sales for the first three or four years, expanding presence beyond chemist stores into grocers, modern trade, quick commerce, and e-commerce.
- API business still internal: Warren API has hardly any external revenue since no approvals have come yet; the time is being used for validation batches, portfolio moves, and creating extra capacities for Patalganga; losses will reduce once API utilization goes up.
- CAPEX on Warren side is now completed: Both the API site and finished product site CAPEX are done; debt repayment remains on track for this year with no major CAPEX spend expected in the second half or even next year.
Aditi Panandikar: "We have many businesses inside Indoco and some of them are really as different as chalk and cheese. So, the OTC business of Warren Remedies and the API manufacturing business of Warren Remedies are very, very different."
FPP and Other Businesses
- FPP turned around within three years of acquisition: Driven by consistent product supply from Goa 2, de-risking Goa 2 with other sites, better planning coordination, and running a very light shift in the US; once the US business reaches a particular size, it is able to generate profits.
- Allied services growing: AnaCipher CRO and Indoco Analytical Solutions grew 20.8%, continuing an encouraging growth trajectory; AnaCipher also cleared an ANVISA inspection.
- API business resilient: API revenues grew 4.6% at ₹45.1 crore, supporting supply chain security; CEPs are already approved for the API plant and DMFs are in FDA books.
- MHRA audit success at Goa Plant-1: A very successful MHRA audit was completed, with the message received on the day of the call; Europe has already approved the Goa site for one injectable.
Aditi Panandikar: "I think we take great pride in the fact that within three years of acquisition, we have been able to turn around FPP."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| USFDA outcome clarity | Earliest indication of which way the response goes | First week of December 2026 |
| Emerging markets recovery | Business expected to come to mark | Q3 FY27 |
| India domestic growth | High single-digit growth | FY27 |
| International growth | Good, decent double-digit, if not more | FY27 |
| Europe/UK growth | 20% plus growth target | Next 1-2 years |
| Debt repayment | On track to repay debt for this year | FY27 |
| CAPEX | Not more than ₹25 crore this year; bare minimum thereafter | FY27 and next year |
| R&D spend | Will not go above 5% of topline (currently 4% YTD) | Ongoing |
| Cash flow conversion | Working to improve OCF to EBITDA conversion back toward 75-90% range | No date |
| US FDA audit for API plant | Hoping for audit, triggered by own formulation team | By Q2 next year (hoping) |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Consolidated revenue | ₹506.9 cr, +7.4% YoY; first time crossing ₹500 cr quarterly |
| Standalone revenue | ₹438.1 cr, +2% YoY |
| Consolidated EBITDA margin | 9.2% at ₹46.4 cr, vs 9.1% YoY and 8.8% QoQ |
| Standalone EBITDA margin | 9.2% at ₹40.3 cr, vs 12.4% YoY and 10.3% QoQ |
| Domestic formulations revenue | ₹212.8 cr, vs ₹226.1 cr YoY |
| International formulations revenue | ₹172 cr, +12.1% YoY |
| Regulated markets revenue | ₹110.9 cr, +21.1% YoY |
| US business revenue | ₹39.1 cr, +16.4% YoY |
| Europe revenue | ₹67.5 cr, +23.5% YoY |
| Emerging markets revenue | ₹61.2 cr, vs ₹61.8 cr YoY |
| API business revenue | ₹45.1 cr, +4.6% YoY |
| AnaCipher CRO and Indoco Analytical Solutions revenue | ₹8.2 cr, +20.8% YoY |
| Cyclopam brand sales | ₹206 cr, crossed ₹200 cr threshold |
| Gastrointestinal portfolio growth | 30.3% YoY |
| Stomatological business growth | 34.8% YoY |
| Freight cost impact | ~₹13 cr additional in the quarter |
| MR productivity (per head yield) | ₹3.3 lakhs |
| R&D spend | 4% of topline on YTD basis |
| Debt repaid in H1 FY27 | ₹65 cr at consolidated level |
| Warren toothpaste division revenue | ~₹36 cr for the quarter |